The idea that YB-1 is a transcription factor that activates IL-6 promoter activity is in agreement with a ChIP sequencing study in trastuzumab-resistant breast cancer cells that identified IL-6 and IL-6R as YB-1 transcriptional targets [61]. This evidence concerns the gene IL6 and breast cancer.